UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 142

Sortiert nach

Cardiovascular Risk-Benefit Profile of Sibutramine

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (5), p.321-334

Scheen, André J.

2010

Volltextzugriff (PDF)

Thiazolidinediones and liver toxicity

Diabetes & metabolism, 2001-06, Vol.27 (3), p.305-313

SCHEEN, A. J

2001

Volltextzugriff (PDF)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

Diabetes, metabolic syndrome and obesity, 2020-01, Vol.13, p.2765-2779

Scheen, André J

2020

Volltextzugriff (PDF)

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

The Lancet (British edition), 2005-04, Vol.365 (9468), p.1389-1397

2005

Volltextzugriff (PDF)

Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system

Drugs (New York, N.Y.), 2004-01, Vol.64 (22), p.2537-2565

SCHEEN, André J

2004

Volltextzugriff (PDF)

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials

Diabetes & metabolism, 2004-12, Vol.30 (6), p.487-496

SCHEEN, A. J

2004

Volltextzugriff (PDF)

Liver abnormalities in severely obese subjects : Effect of drastic weight loss after gastroplasty

International Journal of Obesity, 1998-04, Vol.22 (3), p.222-226

1998

Volltextzugriff (PDF)

Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Drugs (New York, N.Y.), 2003-01, Vol.63 (10), p.933-951

SCHEEN, André J

2003

Volltextzugriff (PDF)

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

Diabetes & metabolism, 2004-12, Vol.30 (6), p.498-505

SCHEEN, A. J

2004

Volltextzugriff (PDF)

Drug interactions of clinical importance with antihyperglycaemic agents : An update

Drug safety, 2005-01, Vol.28 (7), p.601-631

SCHEEN, André J

2005

Volltextzugriff (PDF)

Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

Clinical pharmacokinetics, 2011-01, Vol.50 (1), p.74-74

Scheen, AJ

2011

Volltextzugriff (PDF)

Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

Clinical pharmacokinetics, 2011, Vol.50 (1), p.74-74

Scheen, AJ

2011

Volltextzugriff (PDF)

Clinical pharmacokinetics of metformin

Clinical pharmacokinetics, 1996-05, Vol.30 (5), p.359-371

SCHEEN, A. J

1996

Volltextzugriff (PDF)

PATHOPHYSIOLOGY OF TYPE 2 DIABETES

Acta clinica belgica (English ed. Online), 2003-11, Vol.58 (6), p.335-341

Scheen, A. J.

2003

Volltextzugriff (PDF)

Current management strategies for coexisting diabetes mellitus and obesity

Drugs (New York, N.Y.), 2003-01, Vol.63 (12), p.1165-1184

SCHEEN, Andre J

2003

Volltextzugriff (PDF)

Combined thiazolidinedione-insulin therapy: Should we be concerned about safety?

Drug safety, 2004-01, Vol.27 (12), p.841-856

SCHEEN, André J

2004

Volltextzugriff (PDF)

METFORMIN AND LACTIC ACIDOSIS

Acta clinica belgica (English ed. Online), 2011-09, Vol.66 (5), p.329-331

Scheen, AJ

2011

Volltextzugriff (PDF)

Drug-eluting stents: meta-analysis in diabetic patients

European heart journal, 2004-12, Vol.25 (23), p.2167-2168

2004

Volltextzugriff (PDF)

Roles of Circadian Rhythmicity and Sleep in Human Glucose Regulation

Endocrine reviews, 1997-10, Vol.18 (5), p.716-738

Van Cauter, E.

1997

Volltextzugriff (PDF)

Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life

Patient preference and adherence, 2016-01, Vol.10, p.2261-2270

2016

Volltextzugriff (PDF)

Pharmacological treatment of obesity: present status

International Journal of Obesity, 1999-02, Vol.23 (S1), p.S47-S53

1999

Volltextzugriff (PDF)

Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness

Diabetes/metabolism research and reviews, 2004-05, Vol.20 (3), p.178-188

2004

Volltextzugriff (PDF)

Obesity and liver disease

Baillière's best practice & research. Clinical endocrinology & metabolism, 2002-12, Vol.16 (4), p.703-716

2002

Volltextzugriff (PDF)

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: Achievements and future developments

Drugs (New York, N.Y.), 1997-09, Vol.54 (3), p.355-368

SCHEEN, A. J

1997

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(142)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(129)
Science & Technology
(129)
Humans
(127)
Human Health Sciences
(109)
Sciences De La Santé Humaine
(109)
Endocrinologie, Métabolisme & Nutrition
(103)
Endocrinology, Metabolism & Nutrition
(103)
Endocrinology & Metabolism
(79)
Biological And Medical Sciences
(62)
Medical Sciences
(56)
Male
(49)
Adult
(45)
Female
(38)
Insulin - Blood
(36)
Blood Glucose - Metabolism
(35)
Pharmacie, Pharmacologie & Toxicologie
(34)
Pharmacy, Pharmacology & Toxicology
(34)
Obesity
(32)
Blood Glucose/metabolism
(28)
Insulin Resistance
(26)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiovascular Risk-Benefit Profile of Sibutramine

Thiazolidinediones and liver toxicity

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials

Liver abnormalities in severely obese subjects : Effect of drastic weight loss after gastroplasty

Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

Drug interactions of clinical importance with antihyperglycaemic agents : An update

Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

Clinical pharmacokinetics of metformin

PATHOPHYSIOLOGY OF TYPE 2 DIABETES

OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions

Current management strategies for coexisting diabetes mellitus and obesity

Combined thiazolidinedione-insulin therapy: Should we be concerned about safety?

METFORMIN AND LACTIC ACIDOSIS

Drug-eluting stents: meta-analysis in diabetic patients

Roles of Circadian Rhythmicity and Sleep in Human Glucose Regulation

Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life

Pharmacological treatment of obesity: present status

Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness

Obesity and liver disease

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: Achievements and future developments

Suchergebnisse filtern